U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H42N2O3
Molecular Weight 490.6768
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 6
Charge 0

SHOW SMILES / InChI
Structure of EDASALONEXENT

SMILES

CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(=O)NCCNC(=O)C1=CC=CC=C1O

InChI

InChIKey=JQLBBYLGWHUHRW-KUBAVDMBSA-N
InChI=1S/C31H42N2O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-25-30(35)32-26-27-33-31(36)28-23-21-22-24-29(28)34/h3-4,6-7,9-10,12-13,15-16,18-19,21-24,34H,2,5,8,11,14,17,20,25-27H2,1H3,(H,32,35)(H,33,36)/b4-3-,7-6-,10-9-,13-12-,16-15-,19-18-

HIDE SMILES / InChI

Molecular Formula C31H42N2O3
Molecular Weight 490.6768
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 6
Optical Activity NONE

CAT-1004 (Edasalonexent)is an orally administered small molecule designed to inhibit NF-κB, which is activated from infancy in Duchenne muscular dystrophy and is central to causing muscle damage and preventing muscle regeneration. Structurally CAT-1004 represents covalently links salicylic acid and docosahexaenoic acid -- two compounds known to inhibit NF-κB. . In a Phase 1 study in adults, NF-κB activity in peripheral mononuclear cells was inhibited following a single dose of edasalonexent but not by equimolar doses of salicylic acid and docosahexaenoic acid. Chronic activation of NF-κB is a key driver of muscle degeneration and suppression of muscle regeneration in Duchenne muscular dystrophy, which occurs early in the disease process and precedes loss of muscle function. Salicylic acid prevents NF-κB mediated muscle atrophy and decreases protein catabolism in muscle. Docosahexaenoic acid has been shown to upregulate anti-inflammatory pathways and suppress pro-inflammatory pathways via modulation of NF-κB activity. Edasalonexent is endocytosed and hydrolyzed by intracellular fatty acid amide hydrolase (FAAH) to release salicylic acid and DHA in the intracellular compartment, thus having a potential advantage of selectively delivering higher doses in target muscle cells where FAAH is abundant.

Approval Year

PubMed

PubMed

TitleDatePubMed
A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.
2017 May
Patents

Patents

Sample Use Guides

33, 67 and 100 mg/kg/day
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Thu Jul 06 04:51:56 UTC 2023
Edited
by admin
on Thu Jul 06 04:51:56 UTC 2023
Record UNII
AF3Z6434KS
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
EDASALONEXENT
INN  
INN   USAN  
Official Name English
edasalonexent [INN]
Common Name English
CAT1004
Code English
N-(2-((4Z,7Z,10Z,13Z,16Z,19Z)-DOCOSA-4,7,10,13,16,19-HEXAENAMIDO)ETHYL)-2-HYDROXYBENZAMIDE
Systematic Name English
EDASALONEXENT [USAN]
Common Name English
CAT-1004
Code English
BENZAMIDE, 2-HYDROXY-N-(2-(((4Z,7Z,10Z,13Z,16Z,19Z)-1-OXO-4,7,10,13,16,19-DOCOSAHEXAEN-1-YL)AMINO)ETHYL)-
Systematic Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/15/1560
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
FDA ORPHAN DRUG 453714
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
Code System Code Type Description
PUBCHEM
44626120
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
NCI_THESAURUS
C171665
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
SMS_ID
100000178258
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
INN
10223
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
CAS
1204317-86-1
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
FDA UNII
AF3Z6434KS
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
DRUG BANK
DB15010
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
USAN
JK-104
Created by admin on Thu Jul 06 04:51:56 UTC 2023 , Edited by admin on Thu Jul 06 04:51:56 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> DERIVATIVE
TARGET -> INHIBITOR
PARENT -> DERIVATIVE
Related Record Type Details
ACTIVE MOIETY